pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
793
stories
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
biopharma dive
May 1, 26
Amgen launches late-stage obesity trial in patients who switch from rival drugs
endpoints
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: Hair-raising trial results, and Servier’s M&A wishlist
stat
Apr 30, 26
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
endpoints
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
STAT+: Five-way obesity drug is super effective — in mice
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 30, 26
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
endpoints
Apr 29, 26
STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
stat
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 29, 26
STAT+: A patent win for Pfizer and BridgeBio
stat
Apr 29, 26
STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
stat
Apr 28, 26
STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
stat
Apr 28, 26
STAT+: FDA launches effort to speed up clinical trials, using AI
stat
Apr 28, 26
Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
stat
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
stat
Apr 28, 26
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
stat
Apr 28, 26
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
stat
Apr 28, 26
Lilly strikes second partnership this year for recombinase-based gene editing
endpoints
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
stat
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
Apr 27, 26
Lilly to buy startup Ajax in bid for a better JAK drug
biopharma dive
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
Apr 27, 26
STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
stat
Apr 27, 26
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
endpoints
Apr 27, 26
STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
stat
← prev
page 26 of 27
next →
